

**Curriculum Vitae**

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

| <b>Research &amp; Professional Experience:</b>                            |                     |
|---|---------------------|
| MOORE Clinical Research, Inc., Nurse Practitioner/Clinical Investigator   | March 2015-Present  |
| MinuteClinic, Tampa, FL, Family Nurse Practitioner                        | Sep 2011-April 2015 |
| Galen College of Nursing, Tampa, FL, Adjunct Clinical Instructor          | Oct 2013 -Sep 2016  |
| Brandon Regional Hospital, Brandon, FL, Registered Nurse, Critical Care   | Oct 1995-May 2004   |
| LifePath Hospice and Palliative Care, Tampa, FL, Registered Nurse         | July 2000-Dec 2002  |
| St Mary's Medical Center, Evansville, IN, Registered Nurse, Critical Care | Sep 1994-Sep 1995   |
| Medical Express Staffing, Louisville, KY, Travel Nurse                    | Nov 1993-June 1995  |
| Carle Foundation Hospital, Urbana, IL, Telemetry Nurse                    | Jan 1992-Oct 1993   |

| <b>Education:</b>  |               |
|--|---------------|
| University of South Florida, Tampa, FL Master of Science in Nursing, Family Nurse Practitioner | August 2011   |
| Parkland College, Champaign, IL , Associates Applied Science of Nursing                        | December 1991 |

| <b>Licenses/Certifications:</b>  |             |
|--|-------------|
| Florida Advanced Registered Nurse Practitioner License, ARNP 2769712       | July 2020   |
| BLS, Healthcare Provider   | June 2021   |
| Bloodborne Pathogens & Biomedical Waste Management 29 CFR OSHA Regulations | August 2020 |
| SoCRA Certified Clinical Research Professional (CCRP)                      | May 2022    |

| <b>Training:</b>  |                |
|---|----------------|
| Comprehensive SOP Review  | January 2020   |
| SoCRA's Annual Conference, San Antonio, Texas   | September 2019 |
| GCP Training, NIH   | August 2019    |
| Bloodborne Pathogens & Biomedical Waste Management Training   | August 2019    |
| Comprehensive SOP Review  | January 2019   |
| Human Subject Assurance Training  | December 2018  |
| Adverse Event Collection and Reporting in Clinical Research   | May 2018       |
| Comprehensive SOP Review  | January 2018   |
| Comprehensive SOP Review  | January 2017   |
| Basic HIPAA Training  | January 2017   |
| GCP Training, NIH   | October 2016   |
| National Academy of Dermatology & American College of Dermatology Nurse Practitioners 5 <sup>th</sup> Annual Conf | May 2016       |
| Comprehensive SOP Review  | January 2016   |
| Clinical Investigator GCP & Trials Management Conference, SoCRA   | December 2015  |
| Rosacea Clinical Assessment Training  | August 2015    |
| Atopic Dermatitis Clinical Assessment Training  | August 2015    |
| Plaque Psoriasis Clinical Assessment Training   | August 2015    |
| Actinic Keratosis Clinical Assessment Training  | August 2015    |

*Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS*

**Curriculum Vitae**

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

|   |            |
|---|------------|
| Acne Lesion Count, IGA and Severity Training & Validation                               | June 2015  |
| Biomedical Waste Management & Blood borne Pathogens Training                            | April 2015 |
| Mycology Certification Training (Specimen Collection, KOH Interpretation, Differential) | April 2015 |

**Brief Summary of Skills & Relevant Experience:**

Customer Service, Recruitment, Informed Consent Process, Screening Procedures, UPT Processing & Resulting, Vital Signs, Phlebotomy, PK Sampling, ECGs, KOH Sampling, Processing & Resulting, Physical Exams, Photography, Quality Assurance & Control Procedures, Assessments for: Acne Vulgaris, Rosacea, Actinic Keratosis, Atopic Dermatitis, Tinea Pedis, Onychomycosis, Plaque Psoriasis, Scalp Psoriasis, Herpes Simplex; Protocol Eligibility, Patient Safety Evaluations

**Clinical Trial Experience:**

**ACNE VULGARIS (Validated Acne Rater)**

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.1% (XXXX) to Differin Gel (Adapalene 0.1% XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2020

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Tretinoin Cream 0.025% (XXXX) to Retin-A® (Tretinoin) Cream 0.025% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Lotion 1% (XXXX) to Clindamycin Phosphate Topical Lotion 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle Controlled Study of XXXX in the Treatment of Acne Vulgaris." 2019

"A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone® (Dapsone) Gel, 7.5% (XXXX) and Both Active Treatments to A Placebo Control in the Treatment of Acne Vulgaris." 2019

"A Phase 2, Randomized, Multicenter, Double-Blind, Vehicle Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Daily for 12 Weeks in Subjects with Facial Acne Vulgaris for Treatment of Moderate to Severe Inflammatory Acne Vulgaris" 2019

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Gel 1% (XXXX) to Cleocin T (Clindamycin Phosphate Topical Gel 1% XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study, Comparing Clindamycin 1% to Cleocin T (XXXX, Clindamycin 1% Gel) and Both Active Treatments to a Vehicle Control in the Treatment of Acne." 2018

"A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris." 2018

"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of UHE-101 Cream 1% When Applied Twice Daily for 12 Weeks in Subjects with Facial Acne Vulgaris." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled Parallel-Group Study, Comparing Tretinoin Cream, 0.1% (XXXX) to Retin-A® (Tretinoin) Cream, 0.1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2017

*Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS*

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled Parallel-Group Study, Comparing Tretinoin Cream, 0.05% (XXXX) to Retin-A® (Tretinoin) Cream, 0.05% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2017

"A Multicenter, Randomized, Double Blind, Parallel, Placebo Controlled, Clinical Endpoint Study to Determine the Therapeutic Equivalence of Test Product Benzoyl Peroxide (5%) + Clindamycin Phosphate (Equivalent to 1% Base) Gel and Reference Product BenzaClin® Topical Gel in Patients with Acne Vulgaris." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Adapalene Spray, 0.3% in the Treatment of Acne Vulgaris." 2016

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone (Dapsone) Gel, 7.5%, XXXX, and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2016

"A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products XXXX and XXXX for the Treatment of Acne Vulgaris for 12 Weeks." 2016

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Comparing Dapsone 5% Gel, (XXXX) to Aczone® (XXXX Dapson Gel 5%) and Both Active Ingredients Compared to Placebo (Vehicle) in the Treatment of Acne Vulgaris." 2016

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Dapsone Gel, 5% (XXX) to Aczone® (Dapsone) Gel, 5%, ( XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Clindamycin and Benzoyl Peroxide Gel 1%/5% (XXXX Pharmaceuticals, Inc.) to Benzaclin® (Clindamycin, as Phosphate, 1% and Benzoyl Peroxide 5%) Topical Gel (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene and Benzoyl Peroxide Gel, 0.35/2.5% (XXXX Pharmaceuticals USA, Inc.) to Epiduo® Forte (Adapalene and Benzoyl Peroxide Gel 0.3%/2.5%, XXXX Laboratories, L.P.) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Double-Blind, Randomized, Placebo Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne." 2015

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (XXXX) to the Marketed Product BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (XXXX) in the Treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (XXXX Pharmaceuticals, Inc.) to Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% XXXX Pharmaceuticals LLC) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

*Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS*

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (XXXX Pharmaceuticals, Inc.) to Tactupump™ (XXXX Inc., Adapalene and Benzoyl Peroxide Topical Gel, 0.1%/2.5% w/w) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

XXXX Acne Product Study for the Alleviation of Facial Acne and Associated Redness and Inflammation

"A single-site, randomized, single-blind, comparative therapeutic clinical study against open-label Proactiv+®" 2015

### ACTINIC KERATOSIS

"A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-center, Therapeutic Equivalence Study of Two Fluorouracil 5% Topical Cream Formulations in Adult Subjects with Multiple Actinic Lesions." 2019

### ATOPIC DERMATITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Doxepin Hydrochloride Topical Cream, 5% (XXXX) to Doxepin Hydrochloride topical cream, 5% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Pruritis in Adults with Atopic Dermatitis." 2019

### GLUCOSE RISK ASSESSMENT DEVICE

"Glucose Risk Assessment in Employer Populations" 2019, Principal Investigator

### INFLUENZA

"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza." 2018

"A Clinical Study to Demonstrate the Clinical Significance and Effectiveness of a Combination of Tamiflu® (Oseltamivir Phosphate) and XXX 351 versus Tamiflu® (Oseltamivir Phosphate) Alone as a Treatment for Influenza and the Effectiveness of a Recommended Prevention Dose of Tamiflu® (Oseltamivir Phosphate) Alone versus a Treatment of Tamiflu (Oseltamivir Phosphate) in Combination with XXX 351 as a Treatment for the Prevention of Influenza." 2015

### ONYCHOMYCOSIS

"A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of Novexatin®, 10% Topical Solution (XXXX, USA, Inc.) in Patients with Mild to Moderate Onychomycosis." 2016

### OSTEOARTHRITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Diclofenac Sodium Gel, 1% (XXXX) to Voltaren Gel (Diclofenac Sodium) Gel, 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Patients with Osteoarthritis of the Knee." 2017

"XXXX Product Study for the Alleviation of Pain, Inflammation and Increased Range of Motion in Patients Diagnosed with Mild to Moderate Knee Osteoarthritis; A Single-Site, Randomized, Double-Blind, Placebo-Controlled Comparative Therapeutic Clinical Study Against Osteo Bi-Flex Triple Strength." 2016

*Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS*

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

### PSORIASIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriol and Betamethasone Dipropionate Topical Gel 0.005%/0.064% (XXXX) Dovobet® Gel (Calcipotriol and Betamethasone Dipropionate Gel) 0.005%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Mild to Moderate Body Plaque Psoriasis Vulgaris." 2018

"A Double-Blind, Randomized, Multicenter, Vehicle Controlled, Parallel Group Comparison Study to Determine the Efficacy and Safety of Halobetasol Propionate Spray, 0.05% Versus Vehicle Spray in Subjects with Plaque Psoriasis Receiving Up to Four Weeks of Twice Daily Treatment." 2018

"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018

"A Multi-Center, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis." 2016

"A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days." 2016

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone Topical Spray, 0.15% (XXX Pharmaceuticals, U.S.A., Inc.) in Patients with Mild to Moderate Plaque Psoriasis." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, Comparing Tazarotene Cream 0.05% (XXXX Pharmaceuticals, Inc.) to Tazorac (XXXX, LLC, Tazarotene Cream 0.05% and Both Active Treatments to a Placebo Control in the Treatment of Plaque Psoriasis." 2014

### ROSACEA

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (XXXX) to Soolantra® (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2019

"A Multi-Center, Open-Label, Long-Term Safety Study of XXXX to Evaluate the Safety of XXXX in Papulopustular Rosacea Patients." 2018

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of XXXX in the Treatment of Papulopustular Rosacea." 2018

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azelaic Acid Foam 15% (XXXX) to Finacea (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (XXXX) to Soolantra® (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azelaic Acid Topical Gel 15% (XXXX Pharmaceuticals USA, Inc) to Finacea Gel (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea." 2016

"A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (Azelaic acid) Foam, 15% in Patients with Moderate Facial Rosacea." 2016

*Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS*

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

### SCALP PSORIASIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% (XXXX) to Talconex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical Suspension 0.005%.0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis." 2018

"A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Comparing XXXX Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% to Reference Listed Drug in the Treatment of Scalp Psoriasis." 2017

### TINEA PEDIS

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutics Equivalence of Ketoconazole Cream 2% (XXXX) to Ketoconazole 2% (XXXX) in the Treatment of Tinea Pedis." 2019

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clotrimazole and Betamethasone Dipropionate Cream 1%/0.064% (XXXX) to Lotriderm (Clotrimazole and Betamethasone Dipropionate) Cream 1%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2018

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Naftifine HCL Gel 2% (XXXX) to Naftin (Naftifine HCL) Gel, 2% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Luliconazole Cream 1% (XXXX) to Luzu (Luliconazole) Cream, 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2017

"A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment, Placebo Controlled, Bioequivalence Study of Naftifine Hydrochloride Cream, 2% for Topical Use with that of Naftifine (naftifine hydrochloride) Cream 2% for Topical Use in Patients with Tinea Pedis Using Clinical Endpoints." 2015